OLD Republic International Corp Has $47.60 Million Stake in Pfizer Inc. $PFE

OLD Republic International Corp lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,963,700 shares of the biopharmaceutical company's stock after buying an additional 340,000 shares during the quarter. Pfizer comprises approximately 1.9% of OLD Republic International Corp's investment portfolio, making the stock its 26th largest holding. OLD Republic International Corp's holdings in Pfizer were worth $47,600,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter worth $27,000. North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter worth $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock opened at $23.98 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market cap of $136.34 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The firm's fifty day moving average price is $24.76 and its 200-day moving average price is $24.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 EPS. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.